Our Pipeline

Translating cutting-edge science into breakthrough therapeutics

Pipeline

Development Pipeline

Discovery

Preclinical Validation

Lead Optimization

Ind-enabling

Phase I

Phase II/III

PST010

Oncology

Stage: Lead Optimization

Ena/VASP (PPI)

In-house

collaboration

The fundamental cancer driver Ena/VASP acts as a crucial hub for tumor cell migration and is highly upregulated in invasive cancer forms.

Neoangiogenesis

Metastasis

Protein-protein interaction

Solid tumors

New mode of action

PST020

Infectious Diseases

Stage: Lead Optimization

Target Undisclosed (PPI)

In-house

collaboration

This target is currently undisclosed.

Emerging infectious diseases

Bacterial pathogenesis

PST030

Oncology

Stage: Discovery

Target of Choice (PPI)

In-house

collaboration

This target is currently undisclosed.

Cell growth and proliferation

New mode of action

Solid tumors

PST040

CNS

Stage: Discovery

Target of Choice (PPI)

In-house

collaboration

This target is currently undisclosed.

Neurodegeneration

Neuropathology

Signal transduction

PIPELINE | ONCOLOGY

Aiming to improve survival rates for the most lethal tumor forms, we primarily strive to develop novel and universal cancer therapies.

Lead program

ENA/VASP:
Key-orchestrator of Solid Tumors

Ena/VASP is a highly sought after, yet so far undraggable target, that plays crucial role in the transformation of a benign lesion into an invasive and metastatic tumor.

Cancer Types

Triple Negative Breast Cancer

Pancreatic Cancer

(Non)-Small Cell Lung Cancer

Colon Cancer

Prostate Cancer

Further Solid Tumor Forms

LEAD PROGRAM

Role of ENA/VASP in

Tumor Growth

Tumors result from the unregulated accumulation of cancer cells. This abnormality is highly dependent on neoangiogenesis: the promotion of new blood vessels into the tumor tissue. Within this mechanism, Ena/VASP acts as a fundamental driver.

Metastasis

A malignant tumor is often defined by its capability to invade surrounding tissue and spread throughout the organism. In this context, Ena/VASP is proven to accelerate the directed migration of cancer cells and thus regarded as part of the invasive signature of every solid tumor.